EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6
1 day ago · Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global perspective. In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase ...
News Details - novonordisk.com
4 days ago · Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial. Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction …
Novo Nordisk reports positive data from semaglutide trial for …
1 day ago · Novo Nordisk reports positive data from part one of semaglutide trial for MASH. ESSENCE is a double-blinded, 240-week study that involves 1,200 adults with MASH and stage two or three liver fibrosis. The trial met its primary endpoints, showing a significant improvement in liver fibrosis compared to placebo. Credit: Emily frost/Shutterstock.
Novo Nordisk Reports Headline Results From Part 1 Of ESSENCE …
4 days ago · Novo Nordisk expects to file for regulatory approvals in the US and EU in the first half of 2025. Part 2 of the ESSENCE trial will continue with expected readout in 2029. For More Such Health News ...
News details - novonordisk-us.com
2 days ago · The trial, initiated in 2018, enrolled 17,604 adults and was conducted in 41 countries at more than 800 investigator sites. 4. Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and ...
Latest news - Novo Nordisk
Oct 18, 2024 · 01 November 2024. Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial. Read more. 21 October 2024. Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial.
Novo Nordisk CEO testifies at Senate over weight loss drug prices
Sep 24, 2024 · Novo Nordisk ’s top executive faced a Senate grilling on Tuesday over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars...
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy …
Apr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
News Details - Novo Nordisk
Mar 5, 2024 · Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial. Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW.
News details - Novo Nordisk
Mar 8, 2024 · Novo Nordisk's commitment to the obesity and cardiovascular community is a long-term one, and we are investing significantly to build capacity to meet increasing demand. Please visit WegovySupply.com for the latest information.
- Some results have been removed